Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,041 results that match your search.22,041 results
  • In a rare example of Chinese-Chinese litigation in Europe, telecoms company ZTE has prevailed over its rival Huawei in a patent dispute in Paris
  • The European Commission cunningly kept at least one card up its sleeve when it circulated the draft proposals for reforming the Trade Marks Directive and CTM Regulation last month
  • In the aftermath of the Glivec decision, multinational pharmaceutical companies are concerned about the status of the patent protection in India and are issuing dire warnings about impediments to drug development. Is there really cause for worry?
  • Juan Vanrell, a former partner of Bacot & Bacot and ASIPI president, has launched his own firm in Montevideo, taking five attorneys from his old firm.
  • The India Supreme Court has upheld the Intellectual Property Appellate Board's (IPAB) denial of Novartis's patent application for anti-cancer drug Glivec
  • Today’s blog includes a roundup of news from China and India, the latest views on copyright reform, the Myriad case and Google’s patents pledge
  • Supreme Court justices seemed divided on Monday over the legality of pharmaceutical companies paying generic rivals to keep cheaper alternatives to brand name drugs off the market.
  • Rouse will open a Russia office on May 1, with one executive moving to Moscow and two lawyers coming from Russian firm Shevyrev & Partners.
  • Two patents judges are among 10 new appointments to the Court of Appeal in England & Wales. What does this mean for IP litigation in the UK?
  • There is no need to restate the importance of China to IP owners around the world. But arguably the prime reason China is such a headache for IP practitioners is the speed at which law and practice is changing.